Evidence map›Paper›PMID 20224722›Full record

ArticleInternational journal of clinical and experimental pathology2010

YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas.

Craig Horbinski, Guoji Wang, Clayton A Wiley

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 3 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Circulatory YKL-40 & NLR: Underestimated Prognostic Indicators in Diffuse Glioma.International journal of molecular and cellular medicine · 2018
    Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Brain barriers and a subpopulation of astroglial progenitors of developing human forebrain are immunostained for the glycoprotein YKL-40.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2014
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Craig HorbinskiDepartment of Pathology, Division of Neuropathology, University of Kentucky, 800 Rose Street, Lexington, KY 40536, USA. cho225@email.uky.edu
Guoji Wang
Clayton A Wiley
University of Pittsburgh · USUniversity of Kentucky HealthCare · US

Funding

MIDCAREER INVESTIGATOR AWARDK24MH001717 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WILEY, CLAYTON A. · 1999 to 2009
$1.1M
NIMH NIH HHS K24 MH001717PHS HHS K24 M401717
6 · The paper itself

Abstract

YKL-40 is a secreted chitinase-like molecule whose expression is associated with glioma grade. Expression is higher in astrocytomas than oligodendrogliomas and has been reported to predict shorter survival and radiation resistance in glioblastomas (GBMs). Whether YKL-40 is directly produced by glioma cells or other admixed nonneo-plastic cells, and whether it correlates with 1p/19q status or other hallmark molecular abnormalities, are unclear. A rank-order list of YKL-40 expression was determined immunohistochemically in 79 untreated high-grade adult glio-mas, including 28 anaplastic oligodendrogliomas (AOs) and 51 GBMs. Relative YKL-40 expression was compared with glioma class, key molecular alterations, and immunohistochemical markers via a series of Spearman rank correlations. YKL-40 mRNA in situ hybridization with colocalization assessment via confocal microscopy was also performed. YKL-40 mRNA was abundant in glioma cells as well as reactive astrocytes, but was low in admixed neurons and macrophages. YKL-40 expression was higher in GBMs than AOs (P < 0.0001) and among GBMs, YKL-40 expression was lower in tumors with either EGFR amplification (P = 0.005) or elevated EGFR expression (P = 0.001). Among AOs, no difference in YKL-40 expression was seen in tumors with 1p19q codeletion (P = 0.3), but loss of heterozygosity in 10q23 correlated with increased YKL-40 expression (P = 0.03). These data suggest that YKL-40 is predominantly expressed by neoplastic glial cells and is related to certain key molecular alterations.

Indexed as

AdipokinesAdolescentAdultAgedAged, 80 and overAstrocytomaCentral Nervous System NeoplasmsChitinase-3-Like Protein 1ErbB ReceptorsFemaleGene Expression Regulation, NeoplasticGlioblastomaGliomaGlycoproteinsHumansLectinsAdipokinesCHI3L1 protein, humanChitinase-3-Like Protein 1EGFR protein, humanErbB ReceptorsGlycoproteinsLectins10q1p19qEGFRglioblastomaoligodendrogliomaYKL-40

Identifiers

PMID20224722
PMCPMC2836500
OpenAlexW1884680671

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.